for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Sun Pharma Advanced Research Company

SPRC.NS

Latest Trade

132.50INR

Change

1.80(+1.38%)

Volume

783,061

Today's Range

130.50

 - 

134.95

52 Week Range

112.30

 - 

314.70

As of on the National Stock Exchange of India ∙ Minimum 15 minute delay

Pricing

Previous Close
130.70
Open
130.90
Volume
783,061
3M AVG Volume
16.68
Today's High
134.95
Today's Low
130.50
52 Week High
314.70
52 Week Low
112.30
Shares Out (MIL)
262.05
Market Cap (MIL)
34,721.29
Forward P/E
--
Dividend (Yield %)
--

Next Event

Q3 2020 Sun Pharma Advanced Research Company Ltd Earnings Release

Latest Developments

More

Sun Pharma Advanced Research Company Says U.S. FDA Grants Orphan Drug Designation To Phenobarbital

Sun Pharma Advanced Research Says Two Serious Adverse Events In SCO-088

India's Sun Pharma Advanced Research Company June-Qtr Loss Widens

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Sun Pharma Advanced Research Company

Sun Pharma Advanced Research Company Limited is engaged in the research and experimental development on natural sciences and engineering (Pharmacy). The Company operates through Pharmaceuticals Research & Development segment. Its programs include Xelpros, Elepsia XR, Baclofen GRS, Paclitaxel Injection Concentrate for Nanodispersion (Taclantis), Salmeterol - Fluticasone Dry Powder Inhaler (DPI), SUN-K706, Brimonidine OD, Tizanidine ER, Minocycline Topical and SUN-597 Topical. Xelpros is a Benzalkonium Chloride (BAK)-free Latanoprost eye drops developed with its Swollen Micelle Microemulsion (SMM) technology. Elepsia XR is a once-a-day formulation of Levetiracetam, an antiepileptic agent. Baclofen GRS is a once-a-day formulation of Baclofen, a centrally acting, antispasmodic drug. Taclantis is a Cremophor and Albumin free formulation. Its DPI is a premetered, 60 doses, breath activated device to administer combination of Salmeterol and Fluticasone by inhalation.

Industry

Biotechnology & Drugs

Contact Info

17B Mahal Industrial Estate

Mahakali Caves Road, Andheri (East)

+91.22.66455685

http://www.sunpharma.in/

Executive Leadership

Dilip Shantilal Shanghvi

Executive Chairman of the Board, Managing Director

Anil Raghavan

Chief Executive Officer

Chetan Rajpara

Chief Financial Officer

Debashis Day

Company Secretary

T. Rajamannar

Non-Executive Director

Key Stats

Price To Earnings (TTM)
--
Price To Sales (TTM)
18.93
Price To Book (MRQ)
--
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
--
LT Debt To Equity (MRQ)
--
Return on Investment (TTM)
--
Return on Equity (TTM)
--

Latest News

Latest News

BRIEF-Sun Pharma Advanced Research Co announces top-line results of action study for Baclofen GRS

* Announces top-line results of phase III efficacy study & duration of action study for Baclofen GRS

BRIEF-Sun Pharma Advanced Research Co seeks members' nod to approve transactions with Sun Pharmaceutical Industries Inc

* Seeks members' nod to approve transactions with Sun Pharmaceutical Industries Inc, USA

BRIEF-India's Sun Pharma Advanced Research March-qtr loss widens

* Net loss in March quarter last year was 95.8 million rupees as per Ind-As; total revenue was 434.9 million rupees Source text: http://bit.ly/2q6aPWX Further company coverage:

BRIEF-Sun Pharma Advanced Research to consider raising of additional funds

* Says to consider a proposal for raising of additional funds Source text for Eikon: Further company coverage:

BRIEF-Sun Pharma Advanced Research Co Dec quarter loss widens

* Dec quarter total income from operations 230.5 million rupees

BRIEF-Sun Pharma Advanced Research posts Sept-qtr profit

* Sept quarter total income from operations 948.9 million rupees

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up